Jefferies Starts Protalix BioTherapeutics (PLX) at Hold; Key Driver = Elelyso Commercial Success
Tweet Send to a Friend
Jefferies initiates coverage on Protalix BioTherapeutics (NYSE: PLX) with a Hold. PT $6.00.
Analyst, Eun K. Yang, said, "Positives ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Eun K. Yang, said, "Positives ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
